Milestone Pharmaceuticals Inc.

NASDAQ:MIST

Biotechnology

Healthcare
$0.46 -0.01%

-$0.00 today

Market cap
$57.32M
Beta
0.96
P/E (TTM)
-2.5
EPS (TTM)
-$0.52
52W Low $1.00High $3.06

Volume 2.23M

Average 1.99M

MIST Net Change in Cash

Combined operating, investing, financing, and currency effects on the cash balance during the period.

Milestone Pharmaceuticals Inc.NASDAQ: MIST

Net Change in Cash · Q1 FY2026 · quarter ended Mar 2026

Net change in cash turns negative

Q1 FY2026 net change in cash was -$1.73M, compared with $19.77M a year earlier. Trailing-twelve-month net change in cash was $26.23M.

Context

  • Net change in cash amounted to 3087.5% of revenue in FY2025.
  • Net change in cash increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly net change in cash holds near -$1.73M or moves back toward the trailing-twelve-month quarterly average of $6.56M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$1.73M-106.6% QoQ
Last fiscal yearDec 2025
$47.73M+313.1% YoY
LTMMar 2026
$26.23M-25.0% YoY
Net Change in Cash past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-108.7%——
1 year+313.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Net Change in Cash history

USD · from the cash flow

Latest · FY2025
47.73M USD
Year-over-year change
+313.1%
4-year CAGR
+3.4%

Net Change in Cash vs competitors

How MIST compares with its peers on the latest reported figures

  • Peers report in different currencies, so net change in cash is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -25.0% is the 3rd highest of 8, against a peer median of -123.7%.
  • Net change in cash amounts to 1470.4% of revenue for MIST, versus a peer median of 1092.1%.
MIST Competitors
Net Change in Cash for MIST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MOLNMolecular Partners AGLTM Mar 2026CHF 41.33M CHF-462.5%+5.2%—
IPHAInnate Pharma S.A.FY2025€30.44M EUR+623.1%+15.9%1092.1%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$26.23M USD-25.0%—1470.4%
CRDFCardiff Oncology, Inc.LTM Mar 2026$15.55M USD-386.0%—2962.1%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$6.48M USD+35.0%——
ELTXElicio Therapeutics, Inc.LTM Mar 2026$4.08M USD-162.5%-47.7%—
PEPGPepGen Inc.LTM Mar 2026$1.48M USD-98.4%-39.0%—
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$767K USD-123.7%—24.2%
Peer median (excluding MIST) —-123.7%-16.9%1092.1%

Competitors are the stored peer set for MIST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(42.85M)(58.39M)(59.69M)(41.52M)(63.06M)
Depreciation & Amortization362K89K92K105K114K
Deferred Income Tax00000
Stock-Based Compensation7.28M9.05M9.53M5.78M7.46M
Change in Working Capital1.62M(3.26M)1.24M3.66M2.68M
Accounts Receivables96K(730K)(2.64M)1.46M(1.12M)
Inventory0000(648K)
Accounts Payables00004.43M
Other Working Capital1.52M(2.53M)3.88M2.2M17K
Other Non-Cash Items368K44K2.39M3.13M3.76M
Operating Cash Flow(33.22M)(52.47M)(46.42M)(28.85M)(49.04M)
Capital Expenditures0(272K)(112K)(33K)(302K)
Acquisitions (Net)00000
Purchases of Investments(15M)(85.85M)(137.13M)(113.55M)(82.92M)
Sales of Investments85M29M142M121.87M94.47M
Other Investing Activities00000
Investing Cash Flow70M(57.12M)4.76M8.28M11.25M
Debt Repayment0050M00
Common Stock Issued02.63M027.26M85.53M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities5.06M458K(2.21M)4.86M0
Financing Cash Flow5.06M3.09M47.79M32.12M85.53M
Effect of Forex Changes00000
Net Change in Cash41.83M(106.51M)6.12M11.55M47.73M
Free Cash Flow(33.22M)(52.74M)(46.54M)(28.88M)(49.34M)

Milestone Pharmaceuticals Inc.

NASDAQ:MIST

Intrinsic Alpha fair value

Locked

Current Price

$0.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.